IS2959B - Indasól, bensótríasól og N-hliðstæður þar af sem p38 kínasahindrar - Google Patents

Indasól, bensótríasól og N-hliðstæður þar af sem p38 kínasahindrar

Info

Publication number
IS2959B
IS2959B IS8810A IS8810A IS2959B IS 2959 B IS2959 B IS 2959B IS 8810 A IS8810 A IS 8810A IS 8810 A IS8810 A IS 8810A IS 2959 B IS2959 B IS 2959B
Authority
IS
Iceland
Prior art keywords
indazoles
benzotriazoles
analogs
kinase inhibitors
kinase
Prior art date
Application number
IS8810A
Other languages
English (en)
Other versions
IS8810A (is
Inventor
Munson Mark
A. Mareska David
Kim Youngboo
Groneberg Robert
Rizzi James
Rodriguez Martha
Kim Ganghyeok
Vigers Guy
Rao Chang
Balachari Devan
Harvey Darren
Original Assignee
Array Biopharma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc. filed Critical Array Biopharma Inc.
Publication of IS8810A publication Critical patent/IS8810A/is
Publication of IS2959B publication Critical patent/IS2959B/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IS8810A 2003-03-03 2009-03-16 Indasól, bensótríasól og N-hliðstæður þar af sem p38 kínasahindrar IS2959B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/378,164 US7135575B2 (en) 2003-03-03 2003-03-03 P38 inhibitors and methods of use thereof
US10/688,849 US20040180896A1 (en) 2003-03-03 2003-10-15 P38 inhibitors and methods of use thereof

Publications (2)

Publication Number Publication Date
IS8810A IS8810A (is) 2009-03-16
IS2959B true IS2959B (is) 2017-02-15

Family

ID=32926418

Family Applications (1)

Application Number Title Priority Date Filing Date
IS8810A IS2959B (is) 2003-03-03 2009-03-16 Indasól, bensótríasól og N-hliðstæður þar af sem p38 kínasahindrar

Country Status (28)

Country Link
US (5) US7135575B2 (is)
EP (4) EP1997811B1 (is)
JP (2) JP5424657B2 (is)
KR (3) KR20120037022A (is)
CN (2) CN100579976C (is)
AR (2) AR043451A1 (is)
AT (1) ATE410421T1 (is)
AU (1) AU2009225343B2 (is)
BR (2) BRPI0419305B8 (is)
CL (2) CL2004000416A1 (is)
CO (1) CO5670351A2 (is)
CY (4) CY1108661T1 (is)
DE (1) DE602004016970D1 (is)
DK (5) DK1997809T3 (is)
DO (1) DOP2009000155A (is)
EG (1) EG27049A (is)
ES (4) ES2534859T3 (is)
IL (3) IL170527A (is)
IS (1) IS2959B (is)
NO (1) NO20085373L (is)
NZ (3) NZ542616A (is)
PA (1) PA8596901A1 (is)
PL (1) PL219742B1 (is)
PT (4) PT1997811E (is)
SI (5) SI2039685T1 (is)
TW (2) TWI346663B (is)
UA (2) UA86196C2 (is)
ZA (1) ZA200507874B (is)

Families Citing this family (376)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
US7521447B2 (en) * 2003-03-03 2009-04-21 Array Biopharma Inc. P38 inhibitors and methods of use thereof
US7344716B2 (en) * 2003-05-13 2008-03-18 Depuy Spine, Inc. Transdiscal administration of specific inhibitors of pro-inflammatory cytokines
US7553827B2 (en) * 2003-08-13 2009-06-30 Depuy Spine, Inc. Transdiscal administration of cycline compounds
US8273347B2 (en) * 2003-05-13 2012-09-25 Depuy Spine, Inc. Autologous treatment of degenerated disc with cells
US7429378B2 (en) * 2003-05-13 2008-09-30 Depuy Spine, Inc. Transdiscal administration of high affinity anti-MMP inhibitors
AU2004272104B2 (en) * 2003-09-10 2011-09-08 Icagen, Inc Fused ring heterocycles as potassium channel modulators
WO2005037826A1 (en) 2003-10-17 2005-04-28 Incyte Corporation Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases
US8895540B2 (en) 2003-11-26 2014-11-25 DePuy Synthes Products, LLC Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor
MXPA06007326A (es) 2003-12-23 2007-01-26 Astex Therapeutics Ltd Derivados de pirazol como moduladores de proteina cinasa.
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
RU2006134022A (ru) * 2004-02-27 2008-04-10 Ф.Хоффманн-Ля Рош Аг (Ch) Производные индазола и содержащие их фармацевтические композиции
WO2005085249A1 (en) * 2004-02-27 2005-09-15 F. Hoffmann-La Roche Ag Fused derivatives of pyrazole
CN1934111A (zh) * 2004-02-27 2007-03-21 霍夫曼-拉罗奇有限公司 杂芳基稠合的吡唑并衍生物
ES2475207T3 (es) 2004-07-15 2014-07-10 Tetralogic Pharmaceuticals Corporation Compuestos de unión a IAP
EA012119B1 (ru) * 2004-08-12 2009-08-28 Пфайзер Инк. ПРОИЗВОДНЫЕ ТРИАЗОЛОПИРИДИНСУЛЬФАНИЛА В КАЧЕСТВЕ ИНГИБИТОРОВ p38 MAP КИНАЗЫ
US20100063093A1 (en) 2007-03-28 2010-03-11 Curt Wolfgang Methods for the administration of iloperidone
EP1647549A1 (en) * 2004-10-14 2006-04-19 Laboratoire Theramex Indazoles, benzisoxazoles and benzisothiazoles as estrogenic agents
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
MX2007010371A (es) 2005-02-25 2008-01-11 Tetralogic Pharmaceuticals Inhibidores dimericos iap.
CA2602223A1 (en) * 2005-03-22 2006-10-05 Christian Belmant New class of yo t cells activators and use thereof
ES2382814T3 (es) * 2005-05-17 2012-06-13 Merck Sharp & Dohme Ltd. Ácido cis-4-[(4-clorofenil)sulfonil]-4-(2,5-difluorofenil)ciclohexanopropanoico para el tratamiento del cáncer
MX2007014502A (es) 2005-05-26 2008-02-07 Metabasis Therapeutics Inc Tiromimeticos para el tratamiento de enfermedades del higado graso.
US8343953B2 (en) * 2005-06-22 2013-01-01 Astex Therapeutics Limited Pharmaceutical compounds
WO2006136837A2 (en) * 2005-06-23 2006-12-28 Astex Therapeutics Limited Pharmaceutical combinations comprising pyrazole derivatives as protein kinase modulators
ITRM20050344A1 (it) * 2005-06-30 2007-01-01 Luca Maria De Sali o complessi di sostanze metil-donatrici con acido fitico o suoi derivati e relativo metodo di sintesi.
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
ATE512145T1 (de) 2005-08-11 2011-06-15 Vertex Pharma Modulatoren des cystic fibrosis transmembrane conductance regulators
KR101011956B1 (ko) * 2005-08-25 2011-01-31 에프. 호프만-라 로슈 아게 Ｐ３８ ｍαｐ 키나아제 저해제 및 이의 사용 방법
KR20080039438A (ko) * 2005-08-25 2008-05-07 에프. 호프만-라 로슈 아게 Ｐ３８ ｍαｐ 키나아제 저해제 및 이의 사용 방법
PL1944290T3 (pl) * 2005-09-14 2014-07-31 Ayumi Pharmaceutical Corp Nowa pochodna 1-2-dihydrochinoliny mająca aktywność wiązania glukokortykoidowego receptora
EP1931668A2 (en) * 2005-09-16 2008-06-18 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b]pyridines as phosphodiesterase inhibitors
WO2007031838A1 (en) 2005-09-16 2007-03-22 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
EP1934191B1 (en) * 2005-10-12 2012-03-28 Vertex Pharmaceuticals, Inc. Biphenyl derivatives as modulators of voltage gated ion channels
WO2007047397A2 (en) * 2005-10-13 2007-04-26 Smithkline Beecham Corporation Phenol ethers as modulators of the opioid receptors
ATE446294T1 (de) 2005-11-15 2009-11-15 Array Biopharma Inc N4-phenyl-chinazolin-4-aminderivate und verwandte verbindungen als inhibitoren der erbb-typ-i- rezeptortyrosinkinase zur behandlung hyperproliferativer krankheiten
UA94921C2 (en) * 2005-12-08 2011-06-25 Новартис Аг 1-orthofluorophenyl substituted 1, 2, 5-thiazolidinedione derivatives as ptp-as inhibitors
KR20080098490A (ko) * 2006-01-13 2008-11-10 파마시클릭스, 인코포레이티드 티로신 키나제 억제제 및 이의 용도
RS52298B (sr) * 2006-01-31 2012-12-31 Array Biopharma Inc. Inhibitori kinaze i postupak njihove upotrebe
US8541406B2 (en) * 2006-02-07 2013-09-24 Nv Remynd Thiadiazole derivatives for the treatment of neurodegenerative diseases
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP2540725A1 (de) 2006-05-04 2013-01-02 Boehringer Ingelheim International GmbH Polymorphe von 1-((4-Methyl-chinazolin-2-yl)methyl)-3-methyl-7-(2-butin-1-yl)-8-(3-(R)-amino-piperidin-1-yl)xanthin
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
US8338465B2 (en) * 2006-06-08 2012-12-25 Cornell Research Foundation, Inc. Cyclic carboxylic acid rhodanine derivatives for the treatment and prevention of tuberculosis
US7727978B2 (en) * 2006-08-24 2010-06-01 Bristol-Myers Squibb Company Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors
US20090298811A1 (en) * 2006-09-12 2009-12-03 Pfizer Inc Benzimidazolone derivatives
PL2076501T3 (pl) 2006-09-25 2016-06-30 Ptc Therapeutics Inc Postacie krystaliczne kwasu 3-[5-(2-fluorofenylo)[1,2,4]oksadiazol-3-ilo]-benzoesowego
ES2391910T3 (es) 2006-11-14 2012-12-03 Santen Pharmaceutical Co., Ltd Derivado de 1,2-dihidroquinolina que tiene un grupo (fenil sustituido o heterociclil sustituido)carboniloxi-alquilo inferior y un grupo fenilo introducido por éster como sustituyentes
TW200831085A (en) * 2006-12-13 2008-08-01 Merck & Co Inc Non-nucleoside reverse transcriptase inhibitors
JP2010516702A (ja) * 2007-01-18 2010-05-20 エヴォルヴァ エスアー 置換１，３−ジオキサンのプロドラッグおよびそれらの使用
DE102007009494A1 (de) * 2007-02-27 2008-08-28 Bayer Healthcare Ag Substituierte 4-Aryl-1, 4-dihydro-1,6-naphthyridinamide und ihre Verwendung
US20110105602A2 (en) 2007-03-08 2011-05-05 Daria Mochly-Rosen Mitochondrial Aldehyde Dehydrogenase-2 Modulators and Methods of Use Thereof
US8030344B2 (en) * 2007-03-13 2011-10-04 Methylgene Inc. Inhibitors of histone deacetylase
GB0704932D0 (en) 2007-03-14 2007-04-25 Astex Therapeutics Ltd Pharmaceutical compounds
UA97837C2 (ru) * 2007-03-23 2012-03-26 Эбботт Гмбх Унд Ко. Кг Соединения хинолина для лечения нарушений, которые реагируют на модуляцию рецептора серотонина 5-ht6
AU2008230816B2 (en) * 2007-03-26 2014-09-04 University Of Southern California Methods and compositions for inducing apoptosis by stimulating ER stress
JP5681485B2 (ja) * 2007-04-27 2015-03-11 サイデックス・ファーマシューティカルズ・インコーポレイテッド クロピドグレルおよびスルホアルキルエーテルシクロデキストリンを含有する製剤ならびに使用方法
EP2011786A1 (en) * 2007-07-05 2009-01-07 Laboratorios del Dr. Esteve S.A. Indane-amine derivatives, their preparation and use as medicaments
DE102007032347A1 (de) * 2007-07-11 2009-01-15 Bayer Healthcare Ag Aminoacyl-Prodrugs
WO2009015000A1 (en) * 2007-07-25 2009-01-29 Array Biopharma Inc. Pyrazole urea derivatives used as kinase inhibitors
EP2188257A2 (en) * 2007-08-07 2010-05-26 Cadila Healthcare Limited Sulfoximine derivatives as factor xa inhibitors
TW200908984A (en) * 2007-08-07 2009-03-01 Piramal Life Sciences Ltd Pyridyl derivatives, their preparation and use
US20110118274A1 (en) * 2007-08-23 2011-05-19 Cornell Research Foundation, Inc. Proteasome inhibitors and their use in treating pathogen infection and cancer
WO2009036275A1 (en) * 2007-09-13 2009-03-19 Link Medicine Corporation Treatment of neurodegenerative diseases using indatraline analogs
US8466187B2 (en) 2007-09-18 2013-06-18 Thermolife International, Llc Amino acid compositions
US10646508B1 (en) * 2007-09-18 2020-05-12 Thermolife International, Llc Method of safely administering nitrate dietary supplements and compositions
US10435356B1 (en) 2007-09-18 2019-10-08 Thermolife International, Llc Amino acid compositions
US10426750B1 (en) 2007-09-18 2019-10-01 Thermolife International, Llc Amino acid supplement formulations
JP2011503232A (ja) 2007-11-20 2011-01-27 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 免疫応答の調節
FR2924712B1 (fr) * 2007-12-06 2012-12-21 Univ Maine Derives du gossypol et de l'apogossypol, leurs preparations et leurs applications
EP2070929A1 (en) 2007-12-11 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Alkynylaryl compounds and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
AR069650A1 (es) * 2007-12-14 2010-02-10 Actelion Pharmaceuticals Ltd Derivados de aminopirazol como agonistas no peptidicos del receptor alx humano
US8986696B2 (en) * 2007-12-21 2015-03-24 Depuy Mitek, Inc. Trans-capsular administration of p38 map kinase inhibitors into orthopedic joints
US20090162351A1 (en) * 2007-12-21 2009-06-25 Depuy Spine, Inc. Transdiscal administration of inhibitors of p38 MAP kinase
CA2714111A1 (en) * 2008-02-25 2009-09-03 Merck Sharp & Dohme Corp. Tetrahydro-1h-pyrrolo fused pyridones
CA2716947A1 (en) * 2008-02-29 2009-09-11 Array Biopharma Inc. Imidazo [4,5-b] pyridine derivatives used as raf inhibitors
BRPI0910034B1 (pt) * 2008-03-25 2022-02-08 Affectis Pharmaceuticals Ag Antagonistas do p2x7r e composições farmacêuticas que os compreendem
US20090246234A1 (en) * 2008-04-01 2009-10-01 Benjamin Johnson Therapeutic Treatment Using Niacin for Skin Disorders
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
EP2116539A1 (en) 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof
US8501734B2 (en) * 2008-05-26 2013-08-06 Oncotyrol-Center For Personalized Cancer Medicine Gmbh (Ltd.) Medical intervention in haematological cancers
EP2730579A1 (en) 2008-06-17 2014-05-14 Millennium Pharmaceuticals, Inc. Boronate ester compounds and pharmaceutical compositions thereof
CN102123986B (zh) * 2008-06-25 2013-08-28 学校法人庆应义塾 药物组合物
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
CA2732765A1 (en) * 2008-08-06 2010-02-11 Vertex Pharmaceuticals Incorporated Aminopyridine kinase inhibitors
US8354435B2 (en) 2008-09-08 2013-01-15 The Board Of Trustees Of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase activity and methods of use thereof
CN102149407A (zh) * 2008-09-10 2011-08-10 贝林格尔.英格海姆国际有限公司 治疗糖尿病和相关病症的组合疗法
KR100905419B1 (ko) * 2008-09-11 2009-07-02 연세대학교 산학협력단 세스퀴테르펜 유도체의 용도
CN102170873B (zh) * 2008-10-01 2014-07-30 诺华股份有限公司 用于治疗与hedgehog通路有关的病症的smoothened拮抗
JP5619752B2 (ja) * 2008-10-09 2014-11-05 ニュートゥリー カンパニーリミテッド パンドラチン誘導体またはボエセンベルギアパンドラタ抽出物の新規な用途
AR074797A1 (es) * 2008-10-10 2011-02-16 Japan Tobacco Inc Compuesto de fluoreno , composiciones farmaceuticas , inhibidores de pdhk y pdhk2 , metodos de tratamiento , usos de los mismos y kit comercial
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
CN102202669A (zh) * 2008-10-28 2011-09-28 利兰·斯坦福青年大学托管委员会 醛脱氢酶调节剂及其使用方法
DE102008059133A1 (de) * 2008-11-26 2010-05-27 Merck Patent Gmbh Difluorphenyl-diacylhydrazid-derivate
KR20100060189A (ko) * 2008-11-27 2010-06-07 국립암센터 에타크리닉 산을 포함하는 트란스글루타미나제 관련 질환 예방 또는 치료용 조성물 및 그를 이용하는 트란스글루타미나제 관련 질환 예방 또는 치료 방법
US8362080B2 (en) * 2008-12-18 2013-01-29 Baylor College Of Medicine Increasing glutathione levels for therapy
TWI432188B (zh) * 2008-12-19 2014-04-01 Merz Pharma Gmbh & Co Kgaa 供治療發炎性皮膚疾病之１－胺基－烷基環己烷衍生物類
CN102256976A (zh) 2008-12-23 2011-11-23 贝林格尔.英格海姆国际有限公司 有机化合物的盐形式
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
US9314444B2 (en) * 2009-01-12 2016-04-19 Biokier, Inc. Composition and method for treatment of NASH
KR20110120866A (ko) * 2009-01-12 2011-11-04 바이오키어 인코포레이티드 당뇨병 치료 조성물 및 치료방법
US9006288B2 (en) 2009-01-12 2015-04-14 Biokier, Inc. Composition and method for treatment of diabetes
WO2010081488A1 (en) * 2009-01-15 2010-07-22 Humanitas Mirasole S.P.A. Nitric oxide furoxan derivative compounds endowed with antitumoral activity
US8993808B2 (en) 2009-01-21 2015-03-31 Oryzon Genomics, S.A. Phenylcyclopropylamine derivatives and their medical use
US20100204329A1 (en) * 2009-02-06 2010-08-12 Mcfaul William J Method of using and establishing an absorption rate level and a neuron firing level
WO2010093601A1 (en) * 2009-02-10 2010-08-19 Metabasis Therapeutics, Inc. Novel sulfonic acid-containing thyromimetics, and methods for their use
ES2345241B1 (es) 2009-03-16 2011-09-08 Lipopharma Therapeutics Uso de 2-hidroxiderivados de acidos grasos poliinsaturados como medicamentos.
US8569512B2 (en) * 2009-03-23 2013-10-29 Merck Sharp & Dohme Corp. P2X3 receptor antagonists for treatment of pain
CA2759951C (en) * 2009-05-07 2017-05-02 Gruenenthal Gmbh Substituted phenylureas and phenylamides as vanilloid receptor ligands
US8946204B2 (en) 2009-05-07 2015-02-03 Gruenenthal Gmbh Substituted phenylureas and phenylamides as vanilloid receptor ligands
CA2761455C (en) 2009-05-13 2018-06-12 Cydex Pharmaceuticals, Inc. Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same
ES2524361T3 (es) * 2009-06-12 2014-12-05 United Therapeutics Corporation Iminoazúcares para su uso en el tratamiento de enfermedades por bunyavirus y togavirus
US8283372B2 (en) 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
IN2012DN01983A (is) * 2009-08-24 2015-07-24 Ascepion Pharmaceuticals Inc
WO2011032320A1 (en) * 2009-09-21 2011-03-24 F. Hoffmann-La Roche Ag Novel alkene oxindole derivatives
CA2772188A1 (en) * 2009-09-23 2011-03-31 Pfizer Inc. Gpr 119 modulators
US8859555B2 (en) 2009-09-25 2014-10-14 Oryzon Genomics S.A. Lysine Specific Demethylase-1 inhibitors and their use
EP2486002B1 (en) 2009-10-09 2019-03-27 Oryzon Genomics, S.A. Substituted heteroaryl- and aryl- cyclopropylamine acetamides and their use
KR20240090632A (ko) 2009-11-27 2024-06-21 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
US20130102591A1 (en) * 2010-01-26 2013-04-25 Andrew Lurie Salzman Compositions and methods for prevention and treatment of pulmonary hypertension
EP2353591A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof
US8563610B2 (en) * 2010-02-04 2013-10-22 Rutgers, The State of New Jersey Polyunsaturated fatty acids interactions and oxidative stress disorders
MX2012009377A (es) * 2010-02-11 2012-09-12 Univ Vanderbilt Benzotiazoles y azabenzotiazoles como potenciadores alostericos mglur4, composiciones y metodos para tratar la disfuncion neurologica.
US9006218B2 (en) 2010-02-12 2015-04-14 Chimerix Inc. Nucleoside phosphonate salts
WO2011106574A2 (en) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Inhibitors for antiviral use
WO2011106106A2 (en) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae
JP6182313B2 (ja) * 2010-03-08 2017-08-16 スペクトラム ファーマシューティカルズ インコーポレイテッド 癌治療のためのチオキサントンをベースとしたオートファジー阻害剤療法
CA2796726C (en) * 2010-04-19 2021-02-16 Oryzon Genomics S.A. Lysine specific demethylase-1 inhibitors and their use
WO2011133795A2 (en) * 2010-04-22 2011-10-27 The Brigham And Women's Hospital, Inc. Beta-carbolines as inhibitors of haspin and dyrk kinases
CA2797601A1 (en) 2010-04-26 2011-11-10 Chimerix, Inc. Methods of treating retroviral infections and related dosage regimes
EP2563143A4 (en) * 2010-04-29 2013-09-25 Merck Sharp & Dohme SUBSTITUTED 1,3-BENZOTHIAZOL-2 (3H) -ONE AND [1,3-] THIAZOLO- [5,4-B] PYRIDINE-2 (-1H) -ONE AS POSITIVE ALLOSTERE MODULATORS OF MGLUR2
CN102946875A (zh) 2010-05-05 2013-02-27 贝林格尔.英格海姆国际有限公司 组合疗法
GB201008005D0 (en) * 2010-05-13 2010-06-30 Sentinel Oncology Ltd Pharmaceutical compounds
EP3354635A1 (en) * 2010-05-14 2018-08-01 Agency For Science, Technology And Research Novel antimicrobial compounds and uses thereof
EP2388005A1 (en) 2010-05-21 2011-11-23 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy
MX337106B (es) 2010-05-27 2016-02-12 Targacept Inc Antagonistas no competitivos de receptores nicotinicos.
GB201010359D0 (en) * 2010-06-21 2010-08-04 Univ Nottingham Compounds for treating proliferative disorders
ES2691671T3 (es) * 2010-06-24 2018-11-28 Alkermes Pharma Ireland Limited Profármacos de compuestos NH-acídicos: derivados de éster, carbonato, carbamato y fosfonato
WO2011161161A1 (en) 2010-06-24 2011-12-29 Boehringer Ingelheim International Gmbh Diabetes therapy
TW201204733A (en) * 2010-06-25 2012-02-01 Kowa Co Novel condensed pyridine or condensed pyrimidine derivative, and medicinal agent comprising same
US8846671B2 (en) * 2010-07-01 2014-09-30 Guangzhou Institute Of Biomedicine And Health, Chinese Academy Of Sciences Heterocyclic alkynyl benzene compounds and medical compositions and uses thereof
US20130184273A1 (en) * 2010-07-13 2013-07-18 Bayer Intellectual Property Gmbh Bicyclic pyrimidines
CA2806655A1 (en) 2010-07-28 2012-02-02 Bayer Intellectual Property Gmbh Substituted imidazo[1,2-b]pyridazines
RS55186B1 (sr) * 2010-07-29 2017-01-31 Astellas Pharma Inc Kondenzovana jedinjenja piridina kao ligandi cb2 kanabinoidnog receptora
US9006449B2 (en) 2010-07-29 2015-04-14 Oryzon Genomics, S.A. Cyclopropylamine derivatives useful as LSD1 inhibitors
BR112013002164B1 (pt) 2010-07-29 2021-11-09 Oryzon Genomics S.A. Inibidores de desmetilase à base de arilciclopropilamina de lsd1, seus usos, e composição farmacêutica
EP2415471A1 (en) 2010-08-03 2012-02-08 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in opioid-induced hyperalgesia
PL392436A1 (pl) * 2010-09-17 2012-03-26 Adamed Spółka Z Ograniczoną Odpowiedzialnością Pochodne arylosulfonamidów do leczenia chorób odśrodkowego układu nerwowego
JP2013538784A (ja) * 2010-10-01 2013-10-17 ラクオリア創薬株式会社 Ｔｒｐｍ８拮抗剤としてのスルファモイル安息香酸ヘテロ二環性誘導体
US9061966B2 (en) 2010-10-08 2015-06-23 Oryzon Genomics S.A. Cyclopropylamine inhibitors of oxidases
SG189882A1 (en) * 2010-10-20 2013-06-28 Biota Scient Management Viral polymerase inhibitors
TWI537258B (zh) 2010-11-05 2016-06-11 百靈佳殷格翰國際股份有限公司 六氫茚并吡啶及八氫苯并喹啉之芳基－及雜環芳基羰基衍生物
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
LT2643313T (lt) * 2010-11-24 2016-10-25 Merck Patent Gmbh Chinazolino karboksamido azetidinai
WO2012072713A2 (en) 2010-11-30 2012-06-07 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae
US9096504B2 (en) * 2010-12-01 2015-08-04 Washington State University Controlled chemical release of hydrogen sulfide
US8796338B2 (en) 2011-01-07 2014-08-05 Elcelyx Therapeutics, Inc Biguanide compositions and methods of treating metabolic disorders
US9211263B2 (en) 2012-01-06 2015-12-15 Elcelyx Therapeutics, Inc. Compositions and methods of treating metabolic disorders
US11759441B2 (en) 2011-01-07 2023-09-19 Anji Pharmaceuticals Inc. Biguanide compositions and methods of treating metabolic disorders
EP2661266B1 (en) 2011-01-07 2020-09-16 Anji Pharma (US) LLC Chemosensory receptor ligand-based therapies
US9572784B2 (en) 2011-01-07 2017-02-21 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
US9480663B2 (en) 2011-01-07 2016-11-01 Elcelyx Therapeutics, Inc. Biguanide compositions and methods of treating metabolic disorders
US11974971B2 (en) 2011-01-07 2024-05-07 Anji Pharmaceuticals Inc. Compositions and methods for treating metabolic disorders
EP2668951B9 (en) * 2011-01-25 2017-03-15 Viviabiotech, S.L. 1,2,4-oxadiazole derivatives as drugs modulating the glp-1 peptide receptor
EP2712315B1 (en) 2011-02-08 2021-11-24 Oryzon Genomics, S.A. Lysine demethylase inhibitors for myeloproliferative disorders
US20120208872A1 (en) * 2011-02-11 2012-08-16 Taipei Medical University Use of tea polyphenols for treating and/or preventing nicotine or nicotine-derived compounds or estrogen induced breast cancer
SG192941A1 (en) * 2011-02-25 2013-09-30 Merck Sharp & Dohme Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
US12612370B2 (en) 2011-03-02 2026-04-28 Thermolife International, Llc Amino acid compositions
US8642655B2 (en) * 2011-03-09 2014-02-04 Benjamin Johnson Systems and methods for preventing cancer and treating skin lesions
DK2685827T3 (en) 2011-03-18 2016-05-17 Corcept Therapeutics Inc PYRIMIDIN -cyclohexyl- glucocorticoid receptor MODULATORS
WO2012127466A1 (en) * 2011-03-24 2012-09-27 Bar Ilan University 5-aminolevulinic acid derivatives, methods for their preparation and uses thereof
US8791112B2 (en) * 2011-03-30 2014-07-29 Arrien Pharmaceuticals Llc Substituted 5-(pyrazin-2-yl)-1H-pyrazolo [3, 4-B] pyridine and pyrazolo [3, 4-B] pyridine derivatives as protein kinase inhibitors
CA2833159C (en) 2011-04-13 2019-08-06 Thermolife International, Llc N-acetyl beta alanine methods of use
JP5901025B2 (ja) * 2011-04-19 2016-04-06 第一三共株式会社 テトラヒドロチアゼピン誘導体
US10457659B2 (en) 2011-04-29 2019-10-29 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
EP2524694A1 (en) * 2011-05-19 2012-11-21 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in diabetes type-2 associated pain
US8487008B2 (en) * 2011-06-22 2013-07-16 Universita Degli Studi Di Padova Treatment of muscular dystrophies and associated conditions by administration of monoamine oxidase inhibitors
WO2012177263A1 (en) * 2011-06-24 2012-12-27 Intra-Cellular Therapies, Inc. Compounds and methods of prophylaxis and treatment regarding nictonic receptor antagonists
US8658677B2 (en) * 2011-07-07 2014-02-25 Aria Neurosciences Inc. Pyridyl-2-methylamino compounds, compositions and uses thereof
US8883800B2 (en) 2011-07-15 2014-11-11 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
UA113291C2 (xx) 2011-08-04 2017-01-10 Метаболіти транскломіфену і їх застосування
US8772277B2 (en) * 2011-08-04 2014-07-08 Takeda Pharmaceutical Company Limited Nitrogen-containing heterocyclic compound
US9040567B2 (en) * 2011-08-19 2015-05-26 Emory University BAX agonist, compositions, and methods related thereto
IN2014CN02646A (is) 2011-09-14 2015-08-07 Samumed Llc
CA2848557A1 (en) * 2011-09-14 2013-03-21 Chiesi Farmaceutici S.P.A. Tetrahydrotriazolopyrimidine derivatives as human neutrophil elastase inhibitors
AU2012314587A1 (en) 2011-09-26 2014-03-06 Grünenthal GmbH Aryl or N-heteroaryl substituted methanesulfonamide derivatives as vanilloid receptor ligands
JP2014530198A (ja) * 2011-09-26 2014-11-17 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング バニロイド受容体リガンドとしてのアミン置換メタンスルホンアミド誘導体
JP6046154B2 (ja) 2011-10-20 2016-12-14 オリソン ヘノミクス エセ． アー． Ｌｓｄ１阻害剤としての（ヘテロ）アリールシクロプロピルアミン化合物
EP2768805B1 (en) 2011-10-20 2020-03-25 Oryzon Genomics, S.A. (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors
SG11201401856VA (en) 2011-10-26 2014-05-29 Kempharm Inc Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydromorphone, prodrugs, methods of making and use thereof
EP2780316B1 (en) * 2011-11-13 2020-04-15 Blanchette Rockefeller Neurosciences Institute Esters of dcpla and methods of treatment using the same
WO2013078059A1 (en) * 2011-11-22 2013-05-30 Trustees Of Tufts College Small molecule enhancer for dendritic cell cancer vaccines
EP2787991A1 (en) * 2011-12-05 2014-10-15 Glenmark Pharmaceuticals S.A. Pharmaceutical composition comprising a trpa1 antagonist and an anticholinergic agent
KR20190120430A (ko) 2012-01-06 2019-10-23 엘셀릭스 테라퓨틱스 인코포레이티드 바이구아나이드 조성물 및 대사 장애를 치료하는 방법
EP2800562A2 (en) 2012-01-06 2014-11-12 Elcelyx Therapeutics, Inc. Compositions and methods for treating metabolic disorders
CN102603493B (zh) * 2012-01-17 2014-03-12 青岛农业大学 含氟邻烯丙基苯酚类化合物的制备方法及农用生物活性
AU2013221478B2 (en) * 2012-02-14 2017-06-01 Repros Therapeutics Inc. Selective estrogen receptor modulators with short half-lives and uses thereof
CN102614177B (zh) * 2012-03-06 2014-08-06 北京伟峰益民科技有限公司 卢帕他定在制备治疗慢性阻塞性肺病药物组合物中的应用
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
CN104254326B (zh) * 2012-03-30 2018-09-14 雀巢产品技术援助有限公司 4-氧代-2-戊烯酸和心血管健康
EP2847165A2 (en) * 2012-04-02 2015-03-18 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Indole, indoline derivatives, compositions comprising them and uses thereof
BR112014023670A8 (pt) * 2012-04-04 2017-07-25 Chiesi Farm Spa Composto, composição farmacêutica e suo de um composto
PH12017500997A1 (en) 2012-04-04 2018-02-19 Samumed Llc Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
US8809376B2 (en) * 2012-04-30 2014-08-19 Boehringer Ingelheim International Gmbh Indanyloxydihydrobenzofuranylacetic acids
JP6218811B2 (ja) 2012-05-14 2017-10-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｓｉｒｓ及び／又は敗血症の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
JP6224084B2 (ja) 2012-05-14 2017-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
US12226412B2 (en) 2012-05-25 2025-02-18 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
US20130345205A1 (en) * 2012-06-20 2013-12-26 Vanderbilt University Substituted bicyclic aralkyl pyrazole lactam analogs as allosteric modulators of mglur5 receptors
WO2013192343A1 (en) * 2012-06-20 2013-12-27 Vanderbilt University Substituted bicyclic alkoxy pyrazole analogs as allosteric modulators of mglur5 receptors
EP2875014B1 (en) 2012-07-17 2017-11-29 Washington University Anti-mucus drugs and uses therefor
AU2013302861A1 (en) * 2012-08-13 2015-03-05 The Rockefeller University Treatment and diagnosis of melanoma
ES2877570T3 (es) 2012-08-22 2021-11-17 Univ Cornell Métodos para inhibir fascina
US20150225369A1 (en) * 2012-08-29 2015-08-13 Merck Patent Gmbh Ddr2 inhibitors for the treatment of osteoarthritis
US9278081B2 (en) * 2012-10-04 2016-03-08 University Of The West Indies Extracts from Eucalyptus camaldulensis for the treatment of hyperglycemia and hypertension
US8859598B2 (en) * 2012-10-04 2014-10-14 Allergan, Inc. 1, 2, 4-oxadiazoles azetidine derivatives as sphingosine-1 phosphate receptors modulators
HK1216502A1 (zh) 2012-11-02 2016-11-18 Repros Therapeutics Inc. 用於癌症治療的反式-克羅米芬
US9624214B2 (en) 2012-11-05 2017-04-18 Bayer Pharma Aktiengesellschaft Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
US9657024B2 (en) 2012-11-21 2017-05-23 Stategics, Inc. Substituted triazolo-pyrimidine compounds for modulating cell proliferation, differentiation and survival
HK1212988A1 (zh) * 2012-12-05 2016-07-22 奇斯药制品公司 作为pde-4抑制剂的苯基乙基吡啶衍生物
US20140163025A1 (en) 2012-12-07 2014-06-12 Boehringer Ingelheim International Gmbh Indanyloxydihydrobenzofuranylacetic acids
UY35212A (es) * 2012-12-21 2014-06-30 Gilead Sciences Inc Inhibidores de la quinasa que regula la señal de la apoptosis
EP2943198B1 (en) 2013-01-08 2019-07-17 Samumed, LLC 3-(benzoimidazol-2-yl)-indazole inhibitors of the wnt signaling pathway and therapeutic uses thereof
CU20130027A7 (es) * 2013-02-28 2014-10-30 Ct De Neurociencias De Cuba Chaperoninas químicas como nuevos moduladores moleculares de la beta agregación proteica presente en las enfermedades conformacionales
WO2014153172A1 (en) 2013-03-14 2014-09-25 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
US9120757B2 (en) 2013-03-14 2015-09-01 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
WO2014160185A2 (en) 2013-03-14 2014-10-02 The Board Of Trustees Of The Leland Stanford Junior University Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof
EP2970135B1 (en) 2013-03-14 2018-07-18 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
US9765035B2 (en) 2013-03-14 2017-09-19 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
WO2014153214A1 (en) 2013-03-14 2014-09-25 Epizyme, Inc. Arginine methyl transferase inhibtors and uses thereof
WO2014153208A1 (en) 2013-03-14 2014-09-25 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
KR102028793B1 (ko) 2013-03-14 2019-10-07 에피자임, 인코포레이티드 아르기닌 메틸기 전이효소 억제제 및 이의 용도
EP2970137A1 (en) 2013-03-14 2016-01-20 Epizyme, Inc. Pyrazole derivatives as arginine methyltransferase inhibitors and uses thereof
WO2014151258A1 (en) 2013-03-15 2014-09-25 Janssen Pharmaceutica Nv Substituted pyridine derivatives useful as c-fms kinase inhibitors
US20140335079A1 (en) * 2013-05-07 2014-11-13 Emory University Solenopsin and derivatives, therapeutic compositions, and methods related thereto
JP5740062B1 (ja) * 2013-07-03 2015-06-24 三菱化学フーズ株式会社 毛状疣贅病の予防および／または治療方法
AP2016009020A0 (en) 2013-07-18 2016-02-29 Novartis Ag Autotaxin inhibitors comprising a heteroaromatic ring-benzyl-amide-cycle core
US20150045435A1 (en) * 2013-08-06 2015-02-12 Indiana University Research And Technology Corporation Compounds and methods for treating diabetes
US20160199372A1 (en) * 2013-08-20 2016-07-14 Bristol-Myers Squibb Company Imidazopyridazine kinase inhibitors useful to treating a disease or disorder mediated by aak1, such as alzheimer's disease, bipolar disorder, pain, schizophrenia
WO2015027160A2 (en) * 2013-08-22 2015-02-26 Northeastern University Allosteric modulators of the cannibinoid 1 receptor
MX379061B (es) * 2013-09-13 2025-03-04 Bioventures Llc Preparacion y uso de una composicion para la prevencion y mitigacion de los efectos de la radiacion.
US9353078B2 (en) * 2013-10-01 2016-05-31 New York University Amino, amido and heterocyclic compounds as modulators of rage activity and uses thereof
ES3032935T3 (en) 2013-10-22 2025-07-29 Translate Bio Inc Lipid formulations for delivery of messenger rna
ES2671377T3 (es) * 2013-12-13 2018-06-06 Daiichi Sankyo Company, Limited Derivados de 5-hidroxi-4-(trifluorometil)pirazolopiridina
TN2016000228A1 (en) 2013-12-17 2017-10-06 Esteve Labor Dr SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIs) AND SIGMA RECEPTOR LIGANDS COMBINATIONS.
US9381171B2 (en) * 2013-12-19 2016-07-05 Samsung Electronics Co., Ltd. Composition including dapsone for preventing or treating side effect of steroid in subject and use of the composition
US9862704B2 (en) * 2013-12-20 2018-01-09 AbbVie Deutschland GmbH & Co. KG Oxindole derivatives carrying an amine-substituted piperidyl-acetidinyl substituent and use thereof for treating vasopressine-related diseases
CN104744446B (zh) * 2013-12-30 2019-06-25 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
WO2015106164A1 (en) 2014-01-10 2015-07-16 Rgenix, Inc. Lxr agonists and uses thereof
US9636298B2 (en) 2014-01-17 2017-05-02 Methylgene Inc. Prodrugs of compounds that enhance antifungal activity and compositions of said prodrugs
TWI672141B (zh) 2014-02-20 2019-09-21 美商醫科泰生技 投予ｒｏｓ１突變癌細胞之分子
US9573946B2 (en) * 2014-02-20 2017-02-21 Novita Pharmaceuticals, Inc. Compounds and methods for inhibiting fascin
EP3110449B1 (en) 2014-02-28 2023-06-28 Boehringer Ingelheim International GmbH Medical use of a dpp-4 inhibitor
CN106715426A (zh) 2014-03-21 2017-05-24 拜耳医药股份有限公司 氰基取代的咪唑并[1,2‑a]吡啶甲酰胺及其用途
MA39964A (fr) 2014-05-20 2015-11-26 Millennium Pharm Inc Inhibiteurs du protéasome contenant du bore destinés à être utilisés après une thérapie contre le cancer primaire
MX2016014384A (es) 2014-06-23 2017-01-20 Celgene Corp Apremilast para el tratamiento de una enfermedad del higado o una anormalidad en la funcion del higado.
WO2016040193A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
WO2016040181A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040184A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040190A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
WO2016040180A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040185A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof
US20170304286A1 (en) * 2014-10-24 2017-10-26 Launx Biomedical Co., Ltd. New indication of paroxetine pharmaceutical composition for treating cancer
EP3215140A4 (en) * 2014-11-06 2018-05-02 The Arizona Board of Regents On Behalf of the University of Arizona Compositions and methods of diazeniumdiolate-based prodrugs for treating cancer
ES2882126T3 (es) * 2014-11-07 2021-12-01 Univ Northwestern Inhibición de ornitina aminotransferasa con análogos de GABA para el tratamiento de carcinoma hepatocelular
EP3227287B1 (de) 2014-12-02 2019-08-07 Bayer Pharma Aktiengesellschaft Heteroaryl-substituierte imidazo[1,2-a]pyridine und ihre verwendung
CN107207471B (zh) 2014-12-02 2020-06-26 伊尼塔公司 用于治疗神经母细胞瘤的组合
RU2683274C2 (ru) * 2014-12-02 2019-03-27 Кемфарм, Инк. Бензойная кислота, производные бензойной кислоты и конъюгаты гетероарилкарбоновой кислоты и оксиморфона, их пролекарства, способы получения и применение
WO2016090174A1 (en) * 2014-12-03 2016-06-09 Auckland Uniservices, Ltd. Kinase inhibitor prodrug for the treatment of cancer
EP3230478B1 (en) * 2014-12-12 2023-08-02 Miradx Methods for treating or preventing cancer in a kras-variant patient and for diagnosing risk of developing multiple primary breast tumors
CN107405315A (zh) 2015-01-22 2017-11-28 米托充制药公司 用于治疗神经肌肉、神经变性、自身免疫、发育和/或代谢疾病的脑源性神经营养因子(bdnf)的诱导表达
ES2824552T3 (es) 2015-03-04 2021-05-12 Vanda Pharmaceuticals Inc Método de tratamiento con tradipitant
US20180071376A1 (en) 2015-03-23 2018-03-15 The Brigham And Women`S Hospital, Inc. Tolerogenic nanoparticles for treating diabetes mellitus
CN108135908A (zh) 2015-04-20 2018-06-08 Epizyme股份有限公司 用于治疗癌症的组合疗法
ES2898922T3 (es) * 2015-04-30 2022-03-09 Musc Found For Res Dev Compuestos de oxindol y composiciones farmacéuticas de los mismos
US20160324914A1 (en) 2015-05-05 2016-11-10 Tocol Pharmaceuticals, Llc Use of rice bran oil distillate extract for prevention and mitigation of the effects of radiation
TWI713534B (zh) 2015-06-11 2020-12-21 日商第一三共股份有限公司 5-羥基-4-(三氟甲基)吡唑并吡啶衍生物之結晶及其用途
GB201511382D0 (en) 2015-06-29 2015-08-12 Imp Innovations Ltd Novel compounds and their use in therapy
WO2017023972A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
US10463651B2 (en) 2015-08-03 2019-11-05 Samumed, Llc 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-indazoles and therapeutic uses thereof
US10329309B2 (en) 2015-08-03 2019-06-25 Samumed, Llc 3-(3H-imidazo[4,5-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
WO2017023980A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
US10350199B2 (en) 2015-08-03 2019-07-16 Samumed, Llc 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof
WO2017023996A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
WO2017024003A1 (en) 2015-08-03 2017-02-09 Samumed, Llc 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
WO2017023987A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
US10383861B2 (en) 2015-08-03 2019-08-20 Sammumed, LLC 3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
WO2017023986A1 (en) 2015-08-03 2017-02-09 Samumed, Llc 3-(1h-indol-2-yl)-1h-indazoles and therapeutic uses thereof
US10519169B2 (en) 2015-08-03 2019-12-31 Samumed, Llc 3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
WO2017023984A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
US10166218B2 (en) 2015-08-03 2019-01-01 Samumed, Llc 3-(1H-indol-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
WO2017023988A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
WO2017023989A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
WO2017024004A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
US10226453B2 (en) 2015-08-03 2019-03-12 Samumed, Llc 3-(1H-indol-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
US9675608B2 (en) * 2015-08-26 2017-06-13 Macau University Of Science And Technology Identification of natural small-molecules AMPK activators for treatment of cancers or multidrug-resistant cancers
KR102698411B1 (ko) * 2015-10-08 2024-08-26 쑤저우 운씨엔 이야오 커지 요씨엔 공시 Wnt 신호 전달 경로 억제제 및 이의 치료적 적용
GB201519450D0 (en) * 2015-11-03 2015-12-16 Univ Liverpool Novel treatment
MX380092B (es) 2015-11-06 2025-03-11 Samumed Llc Tratamiento de la osteoartritis.
US9549907B1 (en) * 2015-11-13 2017-01-24 Sovereign Pharmaceuticals, Llc Immediate release oral guaifenesin solution
US10765665B2 (en) * 2015-11-24 2020-09-08 Melin Jeffrey Composition comprising combination of rapamycin and an activator of AMP kinase and use thereof for treating diseases
JP6882289B2 (ja) * 2015-11-25 2021-06-02 コンバージーン・リミテッド・ライアビリティ・カンパニーＣｏｎｖｅｒｇｅｎｅ Ｌｌｃ 二環式ｂｅｔブロモドメイン阻害剤及びその使用
AU2016370846B2 (en) 2015-12-18 2022-08-25 Ignyta, Inc. Combinations for the treatment of cancer
US10494360B2 (en) * 2016-03-09 2019-12-03 Netherlands Translational Research Center B.V Inhibitors of indoleamine 2,3-dioxygenase
US10640487B2 (en) * 2016-03-14 2020-05-05 Teva Pharmaceuticals Usa, Inc. Solid state forms of Nilotinib salts
US10064834B2 (en) * 2016-05-09 2018-09-04 Texas Tech University System Carbidopa for the treatment of cancer
ES2990061T3 (es) * 2016-05-10 2024-11-28 C4 Therapeutics Inc Degronímeros espirocíclicos para la degradación de proteínas diana
US20190054041A1 (en) * 2016-05-26 2019-02-21 Institute Of Tropical Bioscience And Biotechology Chinese Academy Of Tropical Agricultural Sciences Use of nootkatone
MX390577B (es) 2016-06-01 2025-03-20 Samumed Llc Proceso de preparación de n-(5-(3-(7-(3-fluorofenil)-3h-imidazo[4,5-c]piridin-2-il)-1h-indazol-5-il)piridin-3-il)-3-metilbutanamida.
EP3251668A1 (en) 2016-06-02 2017-12-06 Pharmotech SA Cannabidiol compositions and uses thereof
CN109310697A (zh) 2016-06-10 2019-02-05 勃林格殷格翰国际有限公司 利格列汀和二甲双胍的组合
AU2017324510B2 (en) * 2016-09-07 2023-08-31 Temple University - Of The Commonwealth System Of Higher Education Compositions and methods for treatment of insulin resistance
EP3446703A1 (en) * 2017-08-24 2019-02-27 Isofol Medical AB 6r]-mthf multiple bolus administration in 5-fluorouracil based chemotherapy
EP3446704A1 (en) 2017-08-24 2019-02-27 Isofol Medical AB [6r]-mthf - an efficient folate alternative in 5-fluorouracil based chemotherapy
JP2019535672A (ja) 2016-10-21 2019-12-12 サミュメッド リミテッド ライアビリティ カンパニー インダゾール−３−カルボキサミドの使用方法およびｗｎｔ／β−カテニンシグナル伝達経路阻害剤としてのそれらの使用
MA46696A (fr) 2016-11-07 2019-09-11 Samumed Llc Formulations injectables à dose unique prêtes à l'emploi
JP2020500199A (ja) 2016-11-21 2020-01-09 バイキング・セラピューティクス・インコーポレイテッド グリコーゲン蓄積症の治療方法
EP3554263B1 (en) * 2016-12-15 2023-07-19 Société des Produits Nestlé S.A. Compositions and methods that modulate digestibility in a companion animal
US10723716B2 (en) 2016-12-21 2020-07-28 New York University Alpha-helix mimetics as modulators of Abeta self-assembly
US10793530B2 (en) 2017-01-26 2020-10-06 Boehringer Ingelheim International Gmbh Benzylaminopyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
WO2018138030A1 (en) 2017-01-26 2018-08-02 Boehringer Ingelheim International Gmbh Benzyloxypyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
CN110198928B (zh) 2017-01-26 2023-08-29 勃林格殷格翰国际有限公司 苄氧基吡啶基环丙烷甲酸、其药物组合物和用途
US10919859B2 (en) 2017-01-26 2021-02-16 Boehringer Ingelheim International Gmbh Benzylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
JP7049353B2 (ja) 2017-02-08 2022-04-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糖尿病の治療のためのインダニルアミノアザジヒドロベンゾフラニル酢酸、医薬組成物
JP7122256B2 (ja) 2017-02-14 2022-08-19 アイソフォル・メディカル・エービー 血漿２’－デオキシウリジン（ｄＵｒｄ）の増加およびチミジル酸合成酵素阻害のための方法
US10517842B2 (en) * 2017-03-15 2019-12-31 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Methods of modulating miRNA levels and compositions for use in the same
RU2675496C1 (ru) * 2017-03-31 2018-12-20 Федеральное государственное бюджетное учреждение науки Институт нефтехимии и катализа Российской академии наук Способ получения алкиловых эфиров гидроксибензойных кислот
CA3055076C (en) * 2017-03-31 2022-02-22 Corcept Therapeutics, Inc. Glucocorticoid receptor modulators to treat cervical cancer
US20180280319A1 (en) * 2017-04-04 2018-10-04 University Of The Sciences Compounds and compositions for treatment of breast cancer
FR3066393B1 (fr) * 2017-05-16 2019-07-19 Polyneuros Principe actif constitue par un melange de composes poly-lysine et utilisation dans la prevention des avc et le traitement de la phase inflammatoire post-avc
US11491150B2 (en) 2017-05-22 2022-11-08 Intra-Cellular Therapies, Inc. Organic compounds
AU2018280118B2 (en) 2017-06-05 2021-07-15 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis
KR102718538B1 (ko) * 2017-07-19 2024-10-21 이그니타, 인코포레이티드 엔트렉티닙을 포함하는 약학적 조성물
US10639313B2 (en) * 2017-09-01 2020-05-05 Ndsu Research Foundation Compound for inhibition of delta-5-desaturase (D5D) and treatment of cancer and inflammation
AU2018331267B2 (en) 2017-09-13 2024-03-07 Vanda Pharmaceuticals Inc. Improved treatment of atopic dermatitis with tradipitant
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
BR112020006677A2 (pt) 2017-10-05 2020-10-06 Fulcrum Therapeutics, Inc. uso de inibidores p38 para reduzir a expressão de dux4
CN111225662B (zh) 2017-10-17 2022-11-22 伊尼塔公司 药物组合物和剂型
MY201417A (en) 2017-10-20 2024-02-21 Eagle Res Labs Limited Dantrolene prodrugs and methods of their use
WO2019084323A1 (en) * 2017-10-25 2019-05-02 Georgia State University Research Foundation, Inc. CHEMICAL RELEASE SYSTEM DELIVERED BY ENRICHMENT
KR102821964B1 (ko) 2017-11-03 2025-06-19 어클라리스 쎄라퓨틱스, 인코포레이티드 치환된 피롤로피리미딘 jak 억제제 및 이의 제조 및 사용 방법
CA3078981A1 (en) 2017-11-21 2019-05-31 Rgenix, Inc. Polymorphs and uses thereof
ES3053674T3 (en) 2018-03-22 2026-01-23 Viking Therapeutics Inc Crystalline forms and methods of producing crystalline forms of a compound
EP3773579A4 (en) 2018-03-26 2022-03-09 Clear Creek Bio, Inc. COMPOSITIONS AND METHODS FOR INHIBITING DIHYDROOROTATE DEHYDROGENASE
CA3102099C (en) 2018-06-04 2023-09-26 Corcept Therapeutics Incorporated Pyrimidine cyclohexenyl glucocorticoid receptor modulators
CN119080779A (zh) 2018-08-10 2024-12-06 阿克拉瑞斯治疗股份有限公司 吡咯并嘧啶itk抑制剂
EP4523755A3 (en) 2018-09-18 2025-06-11 F. Hoffmann-La Roche AG Quinazoline derivatives as antitumor agents
WO2020117962A1 (en) 2018-12-05 2020-06-11 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis and inflammation
WO2020132046A1 (en) 2018-12-19 2020-06-25 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
US11234971B2 (en) 2018-12-19 2022-02-01 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
FI3897589T3 (fi) 2018-12-19 2026-01-13 Corcept Therapeutics Inc Farmaseuttisia formulaatioita, jotka sisältävät relakorilanttia, heteroaryyliketonifusoitua atsekaliiniyhdistettä
CA3138544A1 (en) 2019-05-02 2020-11-05 Aclaris Therapeutics, Inc. Substituted pyrrolopyridines as jak inhibitors
KR102368413B1 (ko) * 2019-09-25 2022-02-28 경희대학교 산학협력단 시린가레지놀을 포함하는 신경병증성 통증 예방 또는 치료용 조성물
PH12022551430A1 (en) 2019-12-11 2023-11-20 Corcept Therapeutics Inc Methods of treating antipsychotic-induced weight gain with miricorilant
TWI888447B (zh) 2019-12-13 2025-07-01 美商因思博納公司 金屬鹽及其用途
WO2021189018A1 (en) 2020-03-20 2021-09-23 Clear Creek Bio, Inc. Methods of treating viral infections using inhibitors of nucleotide synthesis pathways
JP7791832B2 (ja) 2020-03-26 2025-12-24 バンダ・ファーマシューティカルズ・インコーポレイテッド トラジピタントによる下気道感染症の治療
TW202206062A (zh) 2020-04-24 2022-02-16 美國坦普大學 高等教育聯邦系統 治療非酒精性脂肪肝炎的方法
WO2021226258A1 (en) 2020-05-06 2021-11-11 Corcept Therapeutics Incorporated Formulations of pyrimidine cyclohexyl glucocorticoid receptor modulators
CA3182272A1 (en) 2020-05-06 2021-11-11 Corcept Therapeutics Incorporated Polymorphs of pyrimidine cyclohexyl glucocorticoid receptor modulators
US11285145B2 (en) 2020-05-27 2022-03-29 Corcept Therapeutics Incorporated Concomitant administration of glucocorticoid receptor modulator relacorilant and paclitaxel, a dual substrate of CYP2C8 and CYP3A4
US11071739B1 (en) 2020-09-29 2021-07-27 Genus Lifesciences Inc. Oral liquid compositions including chlorpromazine
US11865139B2 (en) 2020-11-12 2024-01-09 Thermolife International, Llc Method of treating migraines and headaches
JP2024541338A (ja) 2020-11-12 2024-11-08 サーモライフ インターナショナル， エルエルシー 血中酸素飽和度を増大させる方法
MX2023007403A (es) 2020-12-21 2023-08-16 Corcept Therapeutics Inc Método de preparación de los moduladores del receptor de ciclohexilo de pirimidina glucocorticoides.
WO2022134033A1 (en) 2020-12-25 2022-06-30 Corcept Therapeutics Incorporated Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
AU2022220004A1 (en) 2021-02-11 2023-08-17 Thermolife International, Llc A method of administering nitric oxide gas
CN113354558B (zh) * 2021-07-12 2022-03-11 无锡双启科技有限公司 一种2-氨基-5-氟苯腈的制备方法
WO2024052685A1 (en) 2022-09-09 2024-03-14 MyricX Pharma Limited Cytotoxic imidazo[1,2-a]pyridine compounds and their use in therapy
IL319657A (en) 2022-10-06 2025-05-01 Corcept Therapeutics Inc Glucocorticoid receptor modulator formulations
WO2024092195A1 (en) 2022-10-28 2024-05-02 Corcept Therapeutics Incorporated Treatments for amyotrophic lateral sclerosis using dazucorilant
WO2025056518A1 (en) * 2023-09-11 2025-03-20 Univerza V Ljubljani 5,6-DISUBSTITUTED ALKYL 1H AND 2H-INDAZOLES AS DUAL BUTYRYLCHOLINESTERASE AND p38α MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE AND INFLAMMATORY DISEASES

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3755332A (en) * 1971-07-01 1973-08-28 Ciba Geigy Corp Substituted 4 indazolaminoquinolines
JPS5998060A (ja) * 1982-11-27 1984-06-06 Fujisawa Pharmaceut Co Ltd インダゾ−ル誘導体、その製造法および農薬
US4571255A (en) * 1983-12-29 1986-02-18 Ppg Industries, Inc. Subsituted phenoxybenzisoxazole herbicides
SU1545940A3 (ru) 1984-10-19 1990-02-23 Ай-Си-Ай Америказ Инк (Фирма) Способ получени гетероциклических кислот или их солей
US5234942A (en) 1984-10-19 1993-08-10 Ici Americas Inc. Heterocyclic amides and leucotriene antagonistic use thereof
GB8524157D0 (en) 1984-10-19 1985-11-06 Ici America Inc Heterocyclic amides
PL265549A1 (en) 1985-03-26 1988-09-01 The method of manufacture of new heterocyclic amides
JPS6368568A (ja) * 1986-09-10 1988-03-28 Otsuka Pharmaceut Factory Inc ｐ−アミノフエノ−ル誘導体
NZ224714A (en) * 1987-06-01 1990-03-27 Janssen Pharmaceutica Nv Substituted benzotriazole derivatives and pharmaceutical compositions
IL97102A0 (en) 1990-02-16 1992-03-29 Ici Plc Heterocyclic compounds
IE910278A1 (en) 1990-02-16 1991-08-28 Ici Plc Heterocyclic compounds
FI935279L (fi) 1991-05-29 1993-11-26 Pfizer Tricykliska polyhydroxyltyrosinkinasininhibitorer
BR9305569A (pt) 1992-07-03 1995-12-26 Kumiai Chemical Industry Co Derivados heterocíclicos condensados e herbicidas
JPH0841032A (ja) * 1994-05-27 1996-02-13 Mochida Pharmaceut Co Ltd アロマターゼ阻害作用を有する新規なアゾールメチルフェニル誘導体
AU682947B2 (en) 1994-05-27 1997-10-23 Mochida Pharmaceutical Co., Ltd. Novel azolyl methyl phenyl derivatives having aromatase inhibitory activity
KR19990064117A (ko) 1995-10-06 1999-07-26 폴락 돈나 엘. 항암 활성과 사이토킨 억제 활성을 갖는 치환된 이미다졸
US6083949A (en) 1995-10-06 2000-07-04 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
EA002113B1 (ru) 1996-09-04 2001-12-24 Пфайзер Инк. Производные индазола и их использование в качестве ингибиторов фосфодиэстеразы (фдэ) типа iv и продуцирования фактора некроза опухоли (фно)
WO1998013350A1 (en) 1996-09-25 1998-04-02 Zeneca Limited Qinoline derivatives inhibiting the effect of growth factors such as vegf
US6218386B1 (en) 1996-11-08 2001-04-17 Dupont Pharmaceuticals A1-(3-aminoindazol-5-yl)-3 butyl-cyclic urea useful as a HIV protease inhibitor
EA199900452A1 (ru) 1996-11-08 2000-02-28 Дюпон Фармасьютикалз Компани 1-(3-аминоиндазол-5-ил)-3-фенилметилциклические мочевины, полезные в качестве ингибиторов вич-протеазы
US5932570A (en) 1996-11-08 1999-08-03 Dupont Pharmaceuticals Company 1-(3-aminoindazol-5-yl)-3-phenylmethyl-cyclic ureas useful as HIV protease inhibitors
US5945418A (en) 1996-12-18 1999-08-31 Vertex Pharmaceuticals Incorporated Inhibitors of p38
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US5965583A (en) 1997-04-24 1999-10-12 Ortho-Mcneil Pharmaceutical, Inc. Substituted imidazoles useful in the treatment of inflammatory disease
EP1019394A1 (en) 1997-05-22 2000-07-19 G.D. Searle & Co. PYRAZOLE DERIVATIVES AS p38 KINASE INHIBITORS
US6093742A (en) 1997-06-27 2000-07-25 Vertex Pharmaceuticals, Inc. Inhibitors of p38
US6297239B1 (en) 1997-10-08 2001-10-02 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
BR9812944A (pt) 1997-10-20 2000-08-08 Hoffmann La Roche Inibidores bicìclicos da cinase
EP1028953A1 (en) 1997-11-03 2000-08-23 Boehringer Ingelheim Pharmaceuticals Inc. Aromatic heterocyclic compounds as anti-inflammatory agents
IL135714A0 (en) 1997-11-04 2001-05-20 Pfizer Prod Inc Therapeutically active compounds based on indazole bioisostere replacement of catechol in pde4 inhibitors
US6329412B1 (en) 1997-11-04 2001-12-11 Pfizer Inc Bisamidine compounds as antiproliferative agents
IL135900A0 (en) 1997-11-04 2001-05-20 Pfizer Prod Inc Indazole bioisostere replacement of catechol in therapeuticaly active compounds
EA200000835A1 (ru) 1998-02-12 2001-04-23 Юниверсити Оф Делавэр Соединения-катализаторы с бета-дииминатными анионными лигандами и способы полимеризации олефинов
US6589954B1 (en) 1998-05-22 2003-07-08 Scios, Inc. Compounds and methods to treat cardiac failure and other disorders
GB9820767D0 (en) 1998-09-23 1998-11-18 Cerebrus Ltd Chemical compounds VIII
UA73492C2 (en) 1999-01-19 2005-08-15 Aromatic heterocyclic compounds as antiinflammatory agents
CA2360934A1 (en) 1999-02-22 2000-08-31 Lin-Hua Zhang Polycyclo heterocyclic derivatives as antiinflammatory agents
JP2002539206A (ja) 1999-03-12 2002-11-19 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 抗炎症剤としての芳香族複素環化合物
ATE278674T1 (de) 1999-03-12 2004-10-15 Boehringer Ingelheim Pharma Heterocyklischer harnstoff und verwandte verbindungen als entzündungshemmende mittel
WO2000057861A2 (en) 1999-03-29 2000-10-05 Shire Biochem Inc. Use of cytidine derivatives for the treatment of leukaemia
AU4063600A (en) 1999-04-05 2000-10-23 Merck & Co., Inc. A method of treating cancer
US6355636B1 (en) 1999-04-21 2002-03-12 American Cyanamid Company Substituted 3-cyano-[1.7],[1.5], and [1.8] naphthyridine inhibitors of tyrosine kinases
ES2216884T3 (es) 1999-04-21 2004-11-01 Wyeth Holdings Corporation 3-ciano-(1.7),(1.5) y (1.8)-naftiridina sustituidas que son inhibidores de tirosina-quinasas.
JP2003500403A (ja) 1999-05-21 2003-01-07 サイオス，インコーポレーテッド ｐ３８キナーゼのインヒビターとしてのインドール型誘導体
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
CA2374737C (en) 1999-07-09 2008-02-12 Boehringer Ingelheim Pharmaceuticals, Inc. Novel process for synthesis of heteroaryl-substituted urea compounds
JP4234858B2 (ja) 1999-09-21 2009-03-04 東芝テック株式会社 負極性現像剤
AU1899501A (en) * 1999-11-27 2001-06-04 Dong Wha Pharmaceutical Industrial Co., Ltd. Novel 3-nitropyridine derivatives and the pharmaceutical compositions containingsaid derivatives
EP1235806A4 (en) * 1999-11-27 2004-02-04 Dong Wha Pharm Ind Co Ltd NEW 5-PYRIMIDINE CARBOXAMIDE DERIVATIVES AND PHARMACEUTICAL MIXTURES CONTAINING THESE DERIVATIVES
CN1610667A (zh) 1999-11-27 2005-04-27 同和药品工业株式会社 新型3－硝基吡啶衍生物和含有该衍生物的药物组合物
AU4890301A (en) 2000-04-17 2001-10-30 Dong Wha Pharmaceutical Industrial Co., Ltd. 6-methylnicotinamide derivatives as antiviral agents
EP1341782A2 (en) 2000-11-20 2003-09-10 Scios Inc. Inhibitors of p38 kinase
US7105682B2 (en) * 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
US7102009B2 (en) 2001-01-12 2006-09-05 Amgen Inc. Substituted amine derivatives and methods of use
TW593278B (en) 2001-01-23 2004-06-21 Wyeth Corp 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands
HUP0303415A2 (hu) 2001-03-09 2004-01-28 Pfizer Products Inc. Triazolopiridinek, mint gyulladásgátló anyagok és ezeket tartalmazó gyógyszerkészítmények
WO2002100833A1 (en) * 2001-06-12 2002-12-19 Sumitomo Pharmaceuticals Company, Limited Rho KINASE INHIBITORS
BR0212841A (pt) 2001-09-26 2004-08-03 Pharmacia Italia Spa Derivado ativo de aminoindazole como inibidores de cinase, processo para sua preparação e composições farmacêuticas que os contém
EP1438048A1 (en) 2001-10-18 2004-07-21 Boehringer Ingelheim Pharmaceuticals Inc. 1,4-disubstituted benzo-fused urea compounds as cytokine inhibitors
WO2003051847A1 (en) 2001-12-19 2003-06-26 Smithkline Beecham P.L.C. (1-h-indazol-3-yl) -amide derivatives as gsk-3 inhibitors
EP1480973B1 (en) 2002-02-25 2008-02-13 Boehringer Ingelheim Pharmaceuticals Inc. 1,4-disubstituted benzofused cycloalkyl urea compounds useful in treating cytokine mediated diseases
FR2836914B1 (fr) 2002-03-11 2008-03-14 Aventis Pharma Sa Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
FR2836915B1 (fr) 2002-03-11 2008-01-11 Aventis Pharma Sa Derives d'aminoindazoles, procede de preparation et intermediaires de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant
WO2003087072A1 (en) 2002-03-29 2003-10-23 Mochida Pharmaceutical Co., Ltd. Therapeutic agent for endothelial disorder
DE60325984D1 (de) 2002-07-19 2009-03-12 Memory Pharmaceutical Corp 4-aminobenzofuranverbindungen als phosphodiesterase-4-inhibitoren
JP4648703B2 (ja) 2002-09-05 2011-03-09 アベンティス・ファーマ・ソシエテ・アノニム 医薬としての新規なアミノインダゾール誘導体及びこれらを含む医薬組成物
KR20050071598A (ko) 2002-10-24 2005-07-07 메르크 파텐트 게엠베하 라프-키나아제 억제제로서의 메틸렌 우레아 유도체
ES2273047T3 (es) 2002-10-28 2007-05-01 Bayer Healthcare Ag Fenilaminopirimidinas sustituidas con heteroariloxi como inhibidores de rho-cinasa.
US7196082B2 (en) 2002-11-08 2007-03-27 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
AU2003293376A1 (en) 2002-12-10 2004-06-30 Imclone Systems Incorporated Anti-angiogenic compounds and their use in cancer treatment
US7521447B2 (en) * 2003-03-03 2009-04-21 Array Biopharma Inc. P38 inhibitors and methods of use thereof
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
GB0320244D0 (en) 2003-05-06 2003-10-01 Aventis Pharma Inc Pyrazoles as inhibitors of tumour necrosis factor
US7129252B2 (en) 2003-06-16 2006-10-31 Guoqing P Chen Six membered amino-amide derivatives an angiogenisis inhibitors
SE0301906D0 (sv) 2003-06-26 2003-06-26 Astrazeneca Ab New compounds
WO2005004818A2 (en) 2003-07-09 2005-01-20 Imclone Systems Incorporated Heterocyclic compounds and their use as anticancer agents
WO2005023761A2 (en) 2003-09-11 2005-03-17 Kemia, Inc. Cytokine inhibitors
WO2005063715A1 (en) 2003-12-18 2005-07-14 Boehringer Ingelheim Pharmaceuticals, Inc. Polymorph of birb 796, a p38map kinase inhibitor
CN1894240A (zh) 2003-12-22 2007-01-10 伊莱利利公司 阿片受体拮抗剂
WO2006122230A1 (en) 2005-05-11 2006-11-16 Array Biopharma Inc. P38 inhibitors and methods of use thereof
RS52298B (sr) 2006-01-31 2012-12-31 Array Biopharma Inc. Inhibitori kinaze i postupak njihove upotrebe

Also Published As

Publication number Publication date
NZ542616A (en) 2009-02-28
ES2534859T3 (es) 2015-04-29
EP1997811A3 (en) 2009-09-09
SI1997810T1 (sl) 2013-12-31
SI1997811T1 (sl) 2015-07-31
US7799782B2 (en) 2010-09-21
DK1997811T3 (en) 2015-07-06
SI1606283T1 (sl) 2009-04-30
CL2004000416A1 (es) 2005-01-14
SI1997809T1 (sl) 2014-09-30
BRPI0407993A (pt) 2006-03-07
US8518983B2 (en) 2013-08-27
US20040176325A1 (en) 2004-09-09
IS8810A (is) 2009-03-16
NO20085373L (no) 2005-11-29
KR20090021231A (ko) 2009-02-27
US7135575B2 (en) 2006-11-14
DK2039685T3 (da) 2013-03-25
BRPI0407993B8 (pt) 2021-05-25
PT1997811E (pt) 2015-07-29
NZ572694A (en) 2010-04-30
US20090149459A1 (en) 2009-06-11
AR043451A1 (es) 2005-07-27
EP1997811A2 (en) 2008-12-03
CN100579976C (zh) 2010-01-13
EP2039685A2 (en) 2009-03-25
TW200510416A (en) 2005-03-16
US20090143422A1 (en) 2009-06-04
HK1146664A1 (zh) 2011-06-30
JP2009102395A (ja) 2009-05-14
IL196847A0 (en) 2011-07-31
EP1997811B1 (en) 2015-04-08
IL170527A (en) 2011-11-30
ES2433096T3 (es) 2013-12-09
CN1784396A (zh) 2006-06-07
EP2039685B1 (en) 2012-12-26
EP1997809B1 (en) 2014-05-14
CY1108661T1 (el) 2014-04-09
KR20120037022A (ko) 2012-04-18
EP1997809A3 (en) 2009-09-09
BRPI0407993B1 (pt) 2018-05-22
UA103873C2 (ru) 2013-12-10
CN101759645B (zh) 2014-06-25
DK1997809T3 (da) 2014-07-21
ES2315641T3 (es) 2009-04-01
EP1997810B1 (en) 2013-07-31
TWI343386B (en) 2011-06-11
CY1115441T1 (el) 2017-01-04
PT1606283E (pt) 2008-12-29
TW200936590A (en) 2009-09-01
SI2039685T1 (sl) 2013-04-30
CY1116207T1 (el) 2017-02-08
HK1084673A1 (en) 2006-08-04
KR20110091532A (ko) 2011-08-11
PT1997810E (pt) 2013-11-07
ES2484866T3 (es) 2014-08-12
JP2012251003A (ja) 2012-12-20
DOP2009000155A (es) 2010-09-15
NZ582796A (en) 2011-05-27
IL215917A0 (en) 2011-12-29
EP1997810A2 (en) 2008-12-03
JP5424657B2 (ja) 2014-02-26
EG27049A (en) 2015-04-28
EP1997810A3 (en) 2009-12-02
EP2039685A3 (en) 2009-12-02
US8017641B2 (en) 2011-09-13
JP5687259B2 (ja) 2015-03-18
AU2009225343B2 (en) 2012-08-23
US20040180896A1 (en) 2004-09-16
PT1997809E (pt) 2014-08-26
EP1997809A2 (en) 2008-12-03
BRPI0419305B1 (pt) 2019-10-22
PL400577A1 (pl) 2013-02-18
KR101236608B1 (ko) 2013-02-22
CO5670351A2 (es) 2006-08-31
ATE410421T1 (de) 2008-10-15
CY1114554T1 (el) 2016-10-05
US20090136596A1 (en) 2009-05-28
UA86196C2 (uk) 2009-04-10
BRPI0419305B8 (pt) 2021-05-25
PL219742B1 (pl) 2015-07-31
DK1606283T3 (da) 2009-02-09
PA8596901A1 (es) 2004-11-26
CL2009000234A1 (es) 2009-04-24
CN101759645A (zh) 2010-06-30
AR069413A2 (es) 2010-01-20
AU2009225343A1 (en) 2009-11-05
DE602004016970D1 (de) 2008-11-20
DK1997810T3 (da) 2013-10-21
TWI346663B (en) 2011-08-11
ZA200507874B (en) 2007-03-28

Similar Documents

Publication Publication Date Title
IS2959B (is) Indasól, bensótríasól og N-hliðstæður þar af sem p38 kínasahindrar
PL376789A1 (pl) Pochodne aminoindazoli i ich zastosowanie jako inhibitorów kinazy
IL176233A0 (en) Organophosphorous indazole derivatives and use thereof as protein kinase inhibitors
AP2004003161A0 (en) Substituted benzazoles and use thereof as raf kinase inhibitors.
IL173381A0 (en) 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors
GB2424882B (en) Selective kinase inhibitors
PL373649A1 (en) Kinase inhibitors
IL161516A0 (en) Benzimidazoles useful as protein kinase inhibitors
AP2048A (en) Diazepinoindole derivatives as kinase inhibitors
AU2003271566A8 (en) Pyrrolopyrazines as kinase inhibitors
AU2003299651A8 (en) Tyrosine kinase inhibitors
AU2002362895A1 (en) 5-carbamoyl-1,1-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors
PL371512A1 (en) Indazole compounds useful as protein kinase inhibitors
IL173200A0 (en) Piperidyl-quinazoline derivatives as tyrosine kinase inhibitors
AU2003237446A1 (en) Pyrazole-derivatives as p38 kinase inhibitors
AU2002346929A1 (en) 5-acylamino-1,1-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors
ZA200508359B (en) Indazole derivatives as JNK inhibitors
AP2006003549A0 (en) N-substituted benzimidazolyl C-kit inhibitors.
AP2326A (en) Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors.
AP2006003553A0 (en) N-substituted pyrazolyl-amidyl-benzimidazolyl C- kit inhibitors.
EP1581539A4 (en) NEW TYROSINE KINASE HEMMER
EP1558609A4 (en) KINASE INHIBITORS
IL172132A0 (en) Thienopyridone derivatives as kinase inhibitors
AU2003298942A8 (en) Tyrosine kinase inhibitors
GB2423083B (en) Azole-based kinase inhibitors